Polymer-Free Drug-Coated Stent Beats Bare-Metal Stent in Patients With High Bleeding Risk

Lower rates of myocardial infarction and target-lesion revascularization were observed with the coated device despite short dual antiplatelet therapy.

Despite the proven advantages of drug-eluting stents to reduce target-lesion revascularization relative to bare-metal stents (BMS), the latter continue to be used because of the risks of prolonged dual antiplatelet therapy (DAPT) required for drug-eluting stent patients. In this manufacturer-funded, multicenter, double-blind, randomized study, investigators compared a polymer-free drug-coated stent (not currently available in the U.S.) with a similar BMS in 2466 patients at increased risk for bleeding (ClinicalTrials.gov number, NCT01623180). Both groups of patients received a 1-month course of DAPT followed by a single agent.

At about 1 year, target-lesion revascularization occurred in 5.1% of drug-coated stent and 9.8% of BMS recipients (h…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)